The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contributing ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

CHELMSFORD, MA / ACCESSWIRE / December 10, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), the 101-year-old Massachusetts-based global customer experience company, today announced it's collaborating with Reddy ...

Armed with encouraging interim results from its phase 1/2a myelofibrosis trial, Syntara (ASX:SNT) plans to meet the US regulator to discuss a pivotal study aimed at marketing approval for the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A North East accountancy firm has achieved a prestigious accolade for its outstanding commitment to employee training and ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...